Laboratory Diagnosis and Therapeutic Monitoring in Hemophilia: Value of The Chromogenic Activity Assay

Click the “Start Program” button to indicate you have reviewed the CME/CE information for this activity.
Start Program

Release Date: May 31, 2017
Expiration Date: May 31, 2018
Estimated Time to Complete Activity:
1.0 hours
Minimum System Requirements:
  • Internet Explorer 10 (or higher)
  • Mozilla Firefox 48 (or higher)
  • Google Chrome (latest version)
  • Adobe Acrobat 15.0 (or higher)
  • Screen resolution 1024 x 768
Click here to contact Postgraduate Institute for Medicine (PIM)
Target Audience

This activity has been designed to meet the educational needs of pathologists, pathology residents, laboratory directors, laboratory managers and administrators, chief medical technologists, hospital administrators, registered nurses, support staff, and other clinicians who are interested in the management of patients with hemophilia A or hemophilia B.

Educational Objectives
After participating in this activity, participants should be better able to:

  • Review current issues, challenges, and problems related to the laboratory assessment of hemophilia A and B
  • Discuss potential solutions, such as need to test with both chromogenic and clot-based assays to correctly diagnose non-severe hemophilia A, and the need to accurately measure factor activity levels
  • Review challenges facing clinical laboratories when monitoring some of these recombinant replacement products utilizing existing factor assays used in clinical laboratories
  • Discuss advantages and disadvantages of proposed solutions as well as current recommendations (i.e. MASAC)
  • Recognize the need for accuracy of factor assays in pharmacokinetic monitoring of factor levels

Dorothy M. Adcock
Dorothy M. Adcock, M.D.
Medical Director
Colorado Coagulation, Laboratory Corporation of America® Holdings
Englewood, Colorado

Stefan Tiefenbacher
Stefan Tiefenbacher, PhD
Vice President, Laboratory Corporation of America® Holdings
Technical Director of Coagulation
Colorado Coagulation, A LabCorp Specialty Testing Group
Englewood, Colorado

Rajiv K Pruthi
Rajiv K Pruthi, M.B.B.S.
Associate Professor, Mayo Clinic College of Medicine
Co-Director, Special Coagulation Laboratory
Director Comprehensive Hemophilia Center, Mayo Clinic
Rochester, Minnesota

Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine, Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine.

P.A.C.E.® Continuing Education
Postgraduate Institute for Medicine has been approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. This program is approved for up to 1.0 ASCLS P.A.C.E.® contact hour.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Fee Information
There is no fee for this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty Presenter/Planning Committee Reported Financial Relationship
Dorothy Adcock, MD Consulting Fees: Novo Nordisk and Baxalta
Rajiv Pruthi, MBBS Has no real or apparent conflicts of interest to report.
Stefan Tiefenbacher, PhD Consulting Fees: Novo Nordisk
Fees for non-CME/CE Services: Novo Nordisk

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager Reported Financial Relationship
PIM Clinical Reviewers: Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP Have no real or apparent conflicts of interest to report.
ECM: Patrick J. Crowley, MBA, Partner, Chief Executive Officer; Jodi Andrews, BS, Partner, Chief Operating Officer; Larry Rosenberg, PhD, Medical Writer Have no real or apparent conflicts of interest to report.

Disclosure of Unlabled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PIM and Educational Concepts in Medicine do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

This activity is supported by an educational grant from Novo Nordisk.